Lead Product(s): RV001
Therapeutic Area: Oncology
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2020
The phase IIb study is an international, multicenter study, which is expected to recruit more than 175 patients in EU, as well as in the United States.